Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -170.88% | -473.71% | -- | -118.18% | -148.33% |
| Gross Profit | 170.88% | 473.71% | -- | 118.18% | 148.66% |
| SG&A Expenses | 47.88% | 75.94% | 107.01% | 219.64% | 163.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.44% | 20.55% | 58.27% | 161.38% | 135.84% |
| Operating Income | -29.44% | -20.55% | -58.27% | -161.38% | -136.83% |
| Income Before Tax | -46.10% | -39.43% | -75.36% | -143.58% | -125.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.10% | -39.43% | -75.36% | -143.58% | -125.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.10% | -39.43% | -75.36% | -143.58% | -125.79% |
| EBIT | -29.44% | -20.55% | -58.27% | -161.38% | -136.83% |
| EBITDA | -29.46% | -20.49% | -58.20% | -161.39% | -136.89% |
| EPS Basic | 59.07% | 72.95% | 77.45% | 79.26% | 61.55% |
| Normalized Basic EPS | 64.69% | 76.90% | 79.73% | 78.72% | 61.22% |
| EPS Diluted | 59.07% | 72.95% | 77.45% | 79.26% | 61.55% |
| Normalized Diluted EPS | 64.69% | 76.90% | 79.73% | 78.72% | 61.22% |
| Average Basic Shares Outstanding | 115.19% | 167.38% | 314.67% | 1,080.69% | 893.58% |
| Average Diluted Shares Outstanding | 115.19% | 167.38% | 314.67% | 1,080.69% | 893.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |